BULIS VERONICA SANCHEZ enters LYELL IMMUNOPHARMA, INC. with 9.45K shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Derivatives
Filed: 11/10/2025ACC: 0002095702-25-000002
Officer· VP, Corporate Controller
Since Feb 2026
9.45K
Baseline shares
100% direct
9.45K
Direct ownership
1 position
5.30K
Derivative underlying
3 instruments
1
Security positions
All direct
Non-Derivative Holdings1
Common Stock
DirectShares owned9.45K
Total
9.45K direct9.45K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 9.45K | Direct |
| Total | 9.45K | 9.45K direct |
Derivative Holdings3
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
3K
Shares owned
N/A
Exercise price
37.40
Expiration
—
Exercise window
—
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
1.67K
Shares owned
N/A
Exercise price
42.60
Expiration
—
Exercise window
—
Option (right to buy)
DirectUnderlying security
Common Stock
Underlying shares
624.00
Shares owned
N/A
Exercise price
37.40
Expiration
—
Exercise window
—
Total
Underlying
5.30K
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Option (right to buy) Direct | Common Stock | 37.40 | — | — | 3K | N/A |
| Option (right to buy) Direct | Common Stock | 42.60 | — | — | 1.67K | N/A |
| Option (right to buy) Direct | Common Stock | 37.40 | — | — | 624.00 | N/A |
| Total | 5.30K | 0.00 | ||||